MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript

Harrow NASDAQ: HROW executives said the company's first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized that underlying demand for its core ophthalmic products is accelerating.

Harrow (HROW) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.38 per share a year ago.

First Quarter 2026 and Selected Highlights:  VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to deliver 2026 revenue of over $100 million Quarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 million IHEEZO® unit demand increased 18% year-over-year, with 82% of units from retina accounts TRIESENCE® unit demand more than doubled year-over-year, the sixth consecutive quarter of growth Second Quarter revenue expected between $71 million and $81 million Full-year 2026 revenue guidance reaffirmed at $350 million to $365 million Cash and cash equivalents of $94.6 million as of March 31, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the market close.

State of Alaska Department of Revenue lifted its holdings in shares of Harrow, Inc. (NASDAQ: HROW) by 807.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,807 shares of the company's stock after acquiring an additional 14,065 shares

Harrow has delivered a decade-long 40% CAGR in revenue, with robust operating leverage and EBITDA margin expansion. Seasonal weakness in Q1 consistently creates compelling entry points, with share prices typically bottoming near the Q1 report date and rebounding sharply later in the year. HROW's 2026 low of $33 suggests a likely move to $100 within the year, reflecting the historical pattern of annual highs being about 3x annual lows.

NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclonidine hydrochloride ophthalmic solution) has been assigned a permanent J-Code (J2374) by the Centers for Medicare & Medicaid Services (CMS).